Clinical trials and field studies have demonstrated that the Vi capsular polysaccharide vaccine is approximately 60-70% effective in preventing typhoid fever. The vaccine provides protection for at least 3 years, making it a valuable tool in both individual and community health strategies. However, it is important to note that vaccine effectiveness can vary based on factors such as age, geographic location, and the presence of other health conditions.
